



















36. Ma D, Wang J, Zhao Y, Lee WN, Xiao J, Go VL, et al. Inhibition of glycogen phosphorylation induces changes in cellular proteome and signaling pathways in MIA pancreatic cancer cells. *Pancreas* 2012;41:397–408.
37. Preis M, Korc M. Signaling pathways in pancreatic cancer. *Crit Rev Eukaryot Gene Expr* 2011;21:115–29.
38. Du X, Zhao YP, Zhang TP, Zhou L, Chen G, Cui QC, et al. Notch1 contributes to chemoresistance to gemcitabine and serves as an unfavorable prognostic indicator in pancreatic cancer. *World J Surg* 2013;37:1688–94.
39. Fukushima N, Sato N, Prasad N, Leach SD, Hruban RH, Goggins M. Characterization of gene expression in mucinous cystic neoplasms of the pancreas using oligonucleotide microarrays. *Oncogene* 2004;23:9042–51.
40. Miyamoto Y, Maitra A, Ghosh B, Zechner U, Argani P, Iacobuzio-Donahue CA, et al. Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. *Cancer Cell* 2003;3:565–76.
41. Du X, Wang YH, Wang ZQ, Cheng Z, Li Y, Hu JK, et al. [Down-regulation of Notch1 by small interfering RNA enhances chemosensitivity to gemcitabine in pancreatic cancer cells through activating apoptosis activity]. *Zhejiang Da Xue Xue Bao Yi Xue Ban* 2014;43:313–8.
42. Zhou L, Qi L, Jiang L, Zhou P, Ma J, Xu X, et al. Antitumor activity of gemcitabine can be potentiated in pancreatic cancer through modulation of TLR4/NF-kappaB signaling by 6-shogaol. *AAPS J* 2014;16:246–57.
43. Xin Y, Shen XD, Cheng L, Hong DF, Chen B. Perifosine inhibits S6K1-Gli1 signaling and enhances gemcitabine-induced anti-pancreatic cancer efficiency. *Cancer Chemother Pharmacol* 2014;73:711–9.
44. Wang Y, Zhou Y, Jia G, Han B, Liu J, Teng Y, et al. Shikonin suppresses tumor growth and synergizes with gemcitabine in a pancreatic cancer xenograft model: involvement of NF-kappaB signaling pathway. *Biochem Pharmacol* 2014;88:322–33.
45. Deeb D, Gao X, Liu YB, Pindolia K, Gautam SC. Pristimerin, a quinone-methide triterpenoid, induces apoptosis in pancreatic cancer cells through the inhibition of pro-survival Akt/NF-kappaB/mTOR signaling proteins and anti-apoptotic Bcl-2. *Int J Oncol* 2014;44:1707–15.
46. Balic A, Sorensen MD, Trabulo SM, Sainz B Jr, Cioffi M, Vieira CR, et al. Chloroquine targets pancreatic cancer stem cells via inhibition of CXCR4 and hedgehog signaling. *Mol Cancer Ther* 2014;13:1758–71.
47. Sun XD, Liu XE, Huang DS. Curcumin reverses the epithelial-mesenchymal transition of pancreatic cancer cells by inhibiting the Hedgehog signaling pathway. *Oncol Rep* 2013;29:2401–7.
48. Andersson ER, Lendahl U. Therapeutic modulation of Notch signalling—are we there yet? *Nat Rev Drug Discov* 2014;13:357–78.
49. Espinoza I, Miele L. Notch inhibitors for cancer treatment. *Pharmacol Ther* 2013;139:95–110.
50. Oswald F, Liptay S, Adler G, Schmid RM. NF-kappaB2 is a putative target gene of activated Notch-1 via RBP-Jkappa. *Mol Cell Biol* 1998;18:2077–88.
51. Kim SY, Lee IS, Moon A. 2-Hydroxychalcone and xanthohumol inhibit invasion of triple negative breast cancer cells. *Chem Biol Interact* 2013;203:565–72.
52. Kang Y, Park MA, Heo SW, Park SY, Kang KW, Park PH, et al. The radiosensitizing effect of xanthohumol is mediated by STAT3 and EGFR suppression in doxorubicin-resistant MCF-7 human breast cancer cells. *Biochim Biophys Acta* 2013;1830:2638–48.
53. Deeb D, Gao X, Jiang H, Arbab AS, Dulchavsky SA, Gautam SC. Growth inhibitory and apoptosis-inducing effects of xanthohumol, a prenylated chalcone present in hops, in human prostate cancer cells. *Anticancer Res* 2010;30:3333–9.
54. Monteiro R, Calhau C, Silva AO, Pinheiro-Silva S, Guerreiro S, Gartner F, et al. Xanthohumol inhibits inflammatory factor production and angiogenesis in breast cancer xenografts. *J Cell Biochem* 2008;104:1699–707.
55. Liu M, Hansen PE, Wang G, Qiu L, Dong J, Yin H, et al. Pharmacological profile of xanthohumol, a prenylated flavonoid from hops (*Humulus lupulus*). *Molecules* 2015;20:754–79.
56. Albin A, Dell'Eva R, Vene R, Ferrari N, Buhler DR, Noonan DM, et al. Mechanisms of the antiangiogenic activity by the hop flavonoid xanthohumol: NF-kappaB and Akt as targets. *FASEB J* 2006;20:527–9.
57. Colgate EC, Miranda CL, Stevens JF, Bray TM, Ho E. Xanthohumol, a prenylflavonoid derived from hops induces apoptosis and inhibits NF-kappaB activation in prostate epithelial cells. *Cancer Lett* 2007;246:201–9.
58. Dell'Eva R, Ambrosini C, Vannini N, Piaggio G, Albin A, Ferrari N. AKT/NF-kappaB inhibitor xanthohumol targets cell growth and angiogenesis in hematologic malignancies. *Cancer* 2007;110:2007–11.
59. Lee SH, Kim HJ, Lee JS, Lee IS, Kang BY. Inhibition of topoisomerase I activity and efflux drug transporters' expression by xanthohumol. *Arch Pharm Res* 2007;30:1435–9.
60. Monteghirfo S, Tosetti F, Ambrosini C, Stigliani S, Pozzi S, Frassoni F, et al. Antileukemia effects of xanthohumol in Bcr/Abl-transformed cells involve nuclear factor-kappaB and p53 modulation. *Mol Cancer Ther* 2008;7:2692–702.